BeiGene, a global, science─driven biotechnology company, announced that Brukinsa (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have
Log in met Medi-Access
Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen
Australian TGA approves BeiGene's Brukinsa to treat patients with mantle cell lymphoma
Pharma Biz | Geplaatst op 12.10.2021 13:16